ArticleWorld journal of urology2015
Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups.
Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis.Frontiers in oncology · 2021Pooled it
- A molecular landscape tracking the progression of non-muscle invasive bladder cancer.World journal of urology · 2026Review
- HER2 and urothelial carcinoma: current understanding and future directions.Nature reviews. Urology · 2026Review
- Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer.Biomedicines · 2024Article
- A 10-year renaissance of en bloc resection of bladder tumors (ERBT): Are we approaching the peak or is it back to the trough?World journal of urology · 2023Review
- HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.International journal of molecular sciences · 2023Review
- The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study.Frontiers in oncology · 2023Article
- Cancer-Associated Membrane Protein as Targeted Therapy for Bladder Cancer.Pharmaceutics · 2022Review
- Addition of Chromosome 17 Polysomy andCancers · 2022Article
- Non-muscle invasive bladder cancer biomarkers beyond morphology.Frontiers in oncology · 2022Review
- Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy.Scientific reports · 2020Article
- Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.World journal of urology · 2020Article
- Role of tyrosine kinases in bladder cancer progression: an overview.Cell communication and signaling : CCS · 2020Review
- HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy.The Journal of international medical research · 2020Article
- Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer.Journal of cancer research and clinical oncology · 2018Article
- Article
- CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor.BMC cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrent pathological and clinical parameters provide important prognostic information. However, they are still limitations for predicting the true malignant potential of a specific cancer. The aim of this study was to validate the predicting role of HER-2 expression and demonstrated that combination of the high-risk factors with HER-2 expression is more valuable for determining which non-muscle-invasive bladder cancer (NMIBC) is more aggressive. MATERIALS AND
methodsIn total, 238 patients treated by transurethral resection of the bladder tumor were histopathologically confirmed to be NMIBC. Two experienced uropathologists re-reviewed the slides. HER-2 expression was evaluated by immunohistochemistry and scored for intensity and area of staining. The association of HER-2 staining with tumor recurrence and progression was evaluated by univariate and multivariate analyses and Kaplan-Meier survival curves.
resultsIn multivariable analyses, HER-2 expression was an independent risk factor for predicting tumor progression (HR 2.64, p = 0.024). Combining the EORTC risk scores with HER-2 expression status led to more accurate prediction of progression, especially in patients with intermediate- and high-risk EORTC scores (p < 0.0001, log-rank test).
conclusionsHER-2 positivity is prognostic for predicting progression to muscle invasion in NMIBC. Combination of the high-risk factors with HER-2 expression is more valuable for determining which NMIBC is more aggressive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.